SAFETY DATA SHEET
Vaniprevir Formulation

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Vaniprevir Formulation

Manufacturer or supplier’s details
Company : MSD
Address : 855 Leandro N. Alem St., 8 Floor
Buenos Aires, Argentina  C1001AFB
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification
Specific target organ toxicity - repeated exposure (Oral) : Category 2 (gallbladder, Liver)
Short-term (acute) aquatic hazard : Category 3

GHS label elements
Hazard pictograms : [Image]

Signal Word : Warning
Hazard Statements : H373 May cause damage to organs (gallbladder, Liver) through prolonged or repeated exposure if swallowed.
H402 Harmful to aquatic life.

Precautionary Statements : Prevention:
P260 Do not breathe dust.
P273 Avoid release to the environment.
Response:
P314 Get medical advice/ attention if you feel unwell.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.
Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Components</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chemical name</td>
</tr>
<tr>
<td>Glycerides, C8-10</td>
<td>85409-09-2</td>
</tr>
<tr>
<td>Vaniprevir</td>
<td>923590-37-8</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice
In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled
If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact
Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact
If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed
If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders
First Aid responders should pay attention to self-protection,
and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media
Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

 Unsuitable extinguishing media
None known.

Specific hazards during fire fighting
Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Sweep up or vacuum up spillage and collect in suitable container for disposal.
- Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
- Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- Static electricity may accumulate and ignite suspended dust causing an explosion.
- Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage:
- Keep in properly labeled containers.
- Store in accordance with the particular national regulations.

Materials to avoid:
- Do not store with the following product types:
  - Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vaniprevir</td>
<td>923590-37-8</td>
<td>TWA</td>
<td>300 µg/m³</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Engineering measures:
- Ensure adequate ventilation, especially in confined areas.
- Minimize workplace exposure concentrations.
- Apply measures to prevent dust explosions.
- Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Respiratory protection:
- If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
  - Filter type: Particulates type

Hand protection
- Material: Chemical-resistant gloves

Remarks:
- Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!
- For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection:
- Wear the following personal protective equipment:
  - Safety goggles

Skin and body protection:
- Skin should be washed after contact.

Hygiene measures:
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
- When using do not eat, drink or smoke.
- Wash contaminated clothing before re-use.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES
Vaniprevir Formulation

Appearance : powder
Color : tan
Odor : odorless
Odor Threshold : No data available
pH : No data available
Melting point/freezing point : No data available
Initial boiling point and boiling range : No data available
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Density : 1 g/cm³
Solubility(ies)
  Water solubility : No data available
Partition coefficient: n-octanol/water : No data available
Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
  Viscosity, dynamic : No data available
  Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight: No data available
Particle size: No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity: Not classified as a reactivity hazard.
Chemical stability: Stable under normal conditions.
Possibility of hazardous reactions:
- May form explosive dust-air mixture during processing, handling or other means.
- Can react with strong oxidizing agents.

Conditions to avoid:
- Heat, flames and sparks.
- Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

**Glycerides, C8-10:**

**Acute oral toxicity**
- LD50 (Rat): > 5,000 mg/kg
  - Method: OECD Test Guideline 401
  - Remarks: Based on data from similar materials

**Acute inhalation toxicity**
- LD50 (Rat): > 1.86 mg/l
  - Exposure time: 6 h
  - Test atmosphere: dust/mist
  - Remarks: Based on data from similar materials

**Acute dermal toxicity**
- LD50 (Rat): > 2,000 mg/kg
  - Method: OECD Test Guideline 402
  - Assessment: The substance or mixture has no acute dermal toxicity
  - Remarks: Based on data from similar materials

**Vaniprevir:**

**Acute oral toxicity**
- LD50 (Rat): > 750 mg/kg
  - Remarks: No adverse effect has been observed in acute toxicity tests.
- LD0 (Dog): > 300 mg/kg
  - Remarks: No adverse effect has been observed in acute toxicity tests.
LD50 (Mouse): > 2.000 mg/kg  
Remarks: No mortality observed at this dose.

**Skin corrosion/irritation**  
Not classified based on available information.

**Components:**

**Glycerides, C8-10:**
Species: Rabbit  
Method: OECD Test Guideline 404  
Result: No skin irritation  
Remarks: Based on data from similar materials

**Vaniprevir:**
Species: Rabbit  
Result: No skin irritation

**Serious eye damage/eye irritation**  
Not classified based on available information.

**Components:**

**Glycerides, C8-10:**
Species: Rabbit  
Result: No eye irritation  
Method: OECD Test Guideline 405  
Remarks: Based on data from similar materials

**Vaniprevir:**
Species: Bovine cornea  
Result: Mild eye irritation  
Method: Bovine cornea (BCOP)

**Respiratory or skin sensitization**

**Skin sensitization**  
Not classified based on available information.

**Respiratory sensitization**  
Not classified based on available information.

**Components:**

**Glycerides, C8-10:**
Test Type: Buehler Test  
Routes of exposure: Skin contact  
Species: Guinea pig  
Method: OECD Test Guideline 406  
Result: negative  
Remarks: Based on data from similar materials
SAFETY DATA SHEET

Vaniprevir Formulation

Vaniprevir:
Test Type: Local lymph node assay (LLNA)
Species: Mouse
Result: negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Glycerides, C8-10:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
   Method: OECD Test Guideline 471
   Result: negative
   Remarks: Based on data from similar materials

   Test Type: Chromosome aberration test in vitro
   Method: OECD Test Guideline 473
   Result: negative
   Remarks: Based on data from similar materials

   Test Type: In vitro mammalian cell gene mutation test
   Method: OECD Test Guideline 476
   Result: negative
   Remarks: Based on data from similar materials

Vaniprevir:
Genotoxicity in vitro: Test Type: Chromosomal aberration
   Test system: Chinese hamster ovary cells
   Result: negative

   Test Type: Bacterial reverse mutation assay (AMES)
   Result: negative

   Test Type: Alkaline elution assay
   Test system: rat hepatocytes
   Result: negative

Genotoxicity in vivo: Test Type: Micronucleus test
   Species: Mouse
   Application Route: Oral
   Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Vaniprevir:
Species: Rat, male and female
Application Route: Oral
Activity duration: 104 Weeks
   >= 120 mg/kg body weight
Result: negative
Species: Mouse
Application Route: Oral
Activity duration: 6 Months
- >= 300 mg/kg body weight
- 75 mg/kg body weight
Result: negative
Target Organs: gallbladder

Reproductive toxicity
Not classified based on available information.

Components:
Glycerides, C8-10:
Effects on fertility
- Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 422
  - Result: negative
  - Remarks: Based on data from similar materials

Effects on fetal development
- Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
  - Species: Rat
  - Application Route: Ingestion
  - Method: OECD Test Guideline 422
  - Result: negative
  - Remarks: Based on data from similar materials

Vaniprevir:
Effects on fertility
- Test Type: Fertility/early embryonic development
  - Species: Rat, male and female
  - Application Route: Oral
  - General Toxicity Parent: NOAEL: >= 250 mg/kg body weight
  - Result: No effects on fertility.

Effects on fetal development
- Test Type: Development
  - Species: Rat, female
  - Application Route: Oral
  - General Toxicity Maternal: NOAEL: 120 mg/kg body weight
  - Developmental Toxicity: LOAEC F1: 180 mg/kg body weight
  - Symptoms: No specific developmental abnormalities.
  - Result: negative

  - Test Type: Development
    - Species: Rabbit, female
    - Application Route: Oral
    - General Toxicity Maternal: NOAEL: 120 mg/kg body weight
    - Developmental Toxicity: NOAEL F1: >= 240 mg/kg body weight
    - Symptoms: No specific developmental abnormalities.
STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
May cause damage to organs (gallbladder, Liver) through prolonged or repeated exposure if swallowed.

Components:
Vaniprevir:
Routes of exposure: Ingestion
Target Organs: gallbladder, Liver
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:
Glycerides, C8-10:
Species: Rat
NOAEL: >= 1.000 mg/kg
Application Route: Ingestion
Exposure time: 28 Days
Method: OECD Test Guideline 407
Remarks: Based on data from similar materials

Vaniprevir:
Species: Rat
NOAEL: 120 mg/kg
LOAEL: 360 mg/kg
Application Route: Oral
Exposure time: 6 Months
Target Organs: Liver

Species: Dog
NOAEL: 15 mg/kg
LOAEL: 30 mg/kg
Application Route: Oral
Exposure time: 9 Months
Target Organs: Liver, gallbladder
Symptoms: Gastrointestinal disturbance

Species: Mouse
NOAEL: 150 mg/kg
LOAEL: 300 mg/kg
Application Route: Oral
Exposure time: 90 d
Target Organs: Liver, Kidney, Gastrointestinal tract, Heart, gallbladder, Stomach
Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Vaniprevir:
Ingestion: Symptoms: stomach discomfort, Diarrhea, Nausea, Headache

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Glycerides, C8-10:
Toxicity to fish: LL50 (Danio rerio (zebra fish)): > 10 - 100 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 203
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 202
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: NOEC (Desmodesmus subspicatus (green algae)): > 1 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Method: OECD Test Guideline 201
Remarks: Based on data from similar materials

Vaniprevir:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): > 4 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility.

LC50 (Americamysis): > 4 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility.

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 4 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to microorganisms: EC50: > 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC: 1.000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Persistence and degradability

Components:
Glycerides, C8-10:
Biodegradability: Result: Readily biodegradable.
Remarks: Based on data from similar materials

Vaniprevir:
Biodegradability: Result: not rapidly degradable
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:
Glycerides, C8-10:
Partition coefficient: n-octanol/water: log Pow: < 4

Vaniprevir:

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste
SAFETY DATA SHEET

Vaniprevir Formulation

Version 5.1 Revision Date: 16.10.2020 SDS Number: 25767-00017 Date of last issue: 23.03.2020 Date of first issue: 27.10.2014

Handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Argentina. Carcinogenic Substances and Agents Registry: Not applicable

Control of precursors and essential chemicals for the preparation of drugs: Not applicable

International Regulations

The ingredients of this product are reported in the following inventories:

AICS: not determined

DSL: not determined

IECSC: not determined

SECTION 16. OTHER INFORMATION

Further information


Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

AR / Z8